Literature DB >> 4056851

Photoradiation therapy of 9L-gliosarcoma in rats: hematoporphyrin derivative (types I and II) followed by laser energy.

M K Cheng, J McKean, B Mielke, J Tulip, D Boisvert.   

Abstract

Suspensions of 9L-gliosarcoma cells were inoculated into the brain or flank of rats and photoradiation therapy (PRT) was applied to the resulting tumors. The PRT consisted of hematoporphyrin derivative (HpD), type I or II, followed by single-fiber laser energy 24, 48, or 72 h later. Necrotic foci in brain tumors were most numerous following laser exposure 24 h after HpD; they were more than twice as common, and with less damage to healthy tissue, after HpD II than after HpD I with the same laser dose. Neither lifespan nor the final weight of brain tumor was affected by the type of HpD or whether PRT was applied once or twice. In rats with flank tumor, multiple PRT (up to X 4) did not delay tumor growth; also, 11 of 12 PRT-treated flank tumors grew after implantation at various sites in healthy rats. We conclude that HpD II is a more effective photosensitizer than HpD I. However, the value of PRT will be limited until a lethal dose of laser energy can be delivered throughout a tumor without destroying vital healthy tissue.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4056851     DOI: 10.1007/BF00165182

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Photodynamic therapy of malignant tumours.

Authors:  I Diamond; S G Granelli; A F McDonagh; S Nielsen; C B Wilson; R Jaenicke
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

2.  BCNU and X-ray therapy of intracerebral 9L rat tumors.

Authors:  M Barker; D F Deen; D G Baker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

3.  Quantitation of hematoporphyrin derivative in human gliomas, experimental central nervous system tumors, and normal tissues.

Authors:  R E Wharen; R E Anderson; E R Laws
Journal:  Neurosurgery       Date:  1983-04       Impact factor: 4.654

4.  Photoradiation therapy in the treatment of malignant brain tumors: a phase I (feasibility) study.

Authors:  E R Laws; D A Cortese; J H Kinsey; R T Eagan; R E Anderson
Journal:  Neurosurgery       Date:  1981-12       Impact factor: 4.654

5.  Observations in studies of quantitative kinetics of tritium labelled hematoporphyrin derivatives (HpDI and HpDII) in the normal and neoplastic rat brain model.

Authors:  F M Little; C J Gomer; S Hyman; M L Apuzzo
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

6.  Effects of photoradiation therapy on normal rat brain.

Authors:  M K Cheng; J McKean; D Boisvert; J Tulip; B W Mielke
Journal:  Neurosurgery       Date:  1984-12       Impact factor: 4.654

7.  Survival in glioblastoma: historical perspective.

Authors:  M Salcman
Journal:  Neurosurgery       Date:  1980-11       Impact factor: 4.654

8.  Penetration of hematoporphyrin derivative into rat brain and intracerebral 9L glioma tissue.

Authors:  D P Boisvert; J D McKean; J Tulip; J Cummins; M K Cheng
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

9.  Photoradiation therapy for the treatment of malignant tumors.

Authors:  T J Dougherty; J E Kaufman; A Goldfarb; K R Weishaupt; D Boyle; A Mittleman
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

10.  Phototherapy of human tumours using haematoporphyrin derivative.

Authors:  I J Forbes; P A Cowled; A S Leong; A D Ward; R B Black; A J Blake; F J Jacka
Journal:  Med J Aust       Date:  1980-11-01       Impact factor: 7.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.